Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Bifurcated stent company Stentys completes $18 million 'Series B' venture financing
Scottish Equity Partners leads the round; Sofinnova Partners reinvests

News Release

“This financing round will allow us to complete clinical trials and obtain CE Mark for our drug-eluting, bifurcated stent to treat coronary heart disease.”
Gonzague Issenmann, CEO, Stentys

PARIS, March 19, 2008——Medical device pioneer Stentys announced today that it has completed an $18 million ‘Series B’ round of venture financing. The lead investor was UK venture firm Scottish Equity Partners. Series A investor Sofinnova Partners also participated in the B round. Aelios Finance served as financial advisor to Stentys. Brian Kerr, one of the founding directors of Scottish Equity Partners and a Partner in the firm’s Healthcare Group, will join the Stentys Board of Directors.

Coronary artery disease, one of the leading causes of mortality in the world, is caused by fatty lesions that narrow the coronary artery and reduce blood flow, resulting in an often-lethal myocardial infarction (heart attack). Cardiologists have been using stents (small meshed metal tubes) to unclog the artery, but standard stents are simply ill-suited to treat artery bifurcations, the area where one main vessel branches out into two smaller vessels. In fact, the procedure does not work in more than one patient out of five, and these patients must subsequently undergo a second intervention, and quite often open-chest surgery.

“This financing round will allow us to complete clinical trials and obtain CE Mark for our drug-eluting, bifurcated stent, enabling interventional cardiologists to offer their patients the next generation of dedicated bifurcated-stenting procedures,” said Stentys’ CEO and co-founder, Gonzague Issenmann. “We are very proud to have the most prestigious European VCs as our financial backers, and we are delighted to welcome Brian to our Board of Directors.”

“Stentys has achieved a major breakthrough in terms of patient safety, ease of use for cardiologists, and clinical efficacy,” said Brian Kerr. “It has a high-caliber management team, and it has made rapid progress towards obtaining regulatory approval. There is a $1 billion-plus market opportunity for its product, and we are confident that the company will deliver significant value.”

'Sofinnova initially invested in Stentys because we thought that the company potentially had a very unique and simple solution to the bifurcation issue. We also knew management and their capacity to rapidly advance such a project to First in Man clinical trial,” commented Antoine Papiernik, Managing Partner, Sofinnova Partners. “Stentys over-delivered on those milestones, and this explains the success of this fundraising, to which we are participating in an important way. I am also very glad to now count SEP as a partner in developing the company to the next stage.'

“Stentys has come a long way in a short period of time,” concluded Jacques Séguin, MD, PhD, Co-Founder and Non-Executive President of Stentys as well as Founder, Chairman, and CEO of CoreValve. “The fact that two of Europe’s most successful venture capital firms are solidly behind the Company underscores not only the very significant potential of the Stenys bifurcated platform but also the Company’s swift success in validating proof of principle. As its dedicated bifurcation stent shows further efficacy and safety in the clinic, the market for the innovative Stentys devices will watch closely—because cardiologists now consider the current, standard stents as sub-optimal for bifurcations.”

Narrowings at a bifurcation site are quite common. Indeed, 18 percent of percutaneous coronary interventions involve a bifurcation stenosis. Of those, restenosis (re-occurrence of the blockage) occurs in 20-25 percent of bifurcations treated with drug-eluting stents (DES). The patent-pending innovation of Stentys’ bifurcated stent is that the stent-opening for the side branch can be created anywhere in the stent after it is implanted in the vessel. In short, the procedure’s success is independent from

Publisher Contact Information:

Scottish Equity Partners Limited (SEP)
+ 44 141 585 3169

Company profile of Scottish Equity Partners Limited (SEP)
Past press releases of Scottish Equity Partners Limited (SEP).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.